Obsidian Therapeutics, Inc.
18.68USD
-0.0500 (-0.27%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-1.22▼ | $0 | 0 | 0 |
| Next quarter | $-0.41▼ | $0 | 0 | 0 |
| Current year | $-1▼ | $0 | 0 | 0 |
| Next year | $-2.13▼ | $0 | 0 | 0 |
Beat in 1 of the last 1
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-1.22 | $-1.19 | +0.03 (+2.5%) |
2 ratings from 2 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| LifeSci Capital | Initiated | Outperform | $43 | Aug 18, 2026 |
| Piper Sandler | Initiated | Overweight | $42 | Aug 5, 2026 |
8 filings from 5 insiders · 41 buy / 18 sell over 6m
Officers and directors of OBX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CHANG NANCY TDirector and Beneficial Owner of more than 10% of a Class of Security | Other | 661.3k | — | — | May 15, 2026 |
| FRIEDMAN MICHAEL RDirector | Otherindirect | 2.99M | — | — | May 15, 2026 |
| EMERALD BIOVENTURES LLCBeneficial Owner of more than 10% of a Class of Security | Otherindirect | 20.81M | — | — | May 15, 2026 |
| CHANG NANCY TDirector and Beneficial Owner of more than 10% of a Class of Security | Other | 1.18M | — | — | Apr 7, 2026 |
| FRIEDMAN MICHAEL RDirector | Otherindirect | 5.34M | — | — | Apr 7, 2026 |
| SORENSEN J. MELChief Executive Officer | Sell | 70.0k | $0.02 | $1k | Nov 20, 2025 |
| SORENSEN MELINDAChief Executive Officer | Sell | 70.0k | $0.02 | $1k | Nov 20, 2025 |
| CHANG NANCY TDirector and Beneficial Owner of more than 10% of a Class of Security | Buy | 7.64M | $0.07 | $500k | Dec 30, 2024 |
No analyst notes on OBX yet.
Analyst Ratings
2 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 2 | 0 | 0 | 0 | Buy1.67 |